{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:18Z","timestamp":1793502918046,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jbspin.2025.105954","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:28:08Z","timestamp":1756402088000},"page":"105954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Strategies for denosumab discontinuation in postmenopausal osteoporosis"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4293-8596","authenticated-orcid":false,"given":"Yannick","family":"Degbo\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Couture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jbspin.2025.105954_bib0305","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105954_bib0310","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105954_bib0315","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105954_bib0320","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105954_bib0325","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105954_bib0330","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/jbmr.2236","article-title":"Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension","volume":"29","author":"Brown","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105954_bib0335","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jbspin.2018.02.009","article-title":"2018 update of French recommendations on the management of postmenopausal osteoporosis","volume":"85","author":"Briot","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.jbspin.2025.105954_bib0340","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105954_bib0345","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","article-title":"Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective","volume":"27","author":"Boonen","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105954_bib0350","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105954_bib0355","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105954_bib0360","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105954_bib0365","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105954_bib0370","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"18","key":"10.1016\/j.jbspin.2025.105954_bib0375","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105954_bib0380","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","article-title":"Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone","volume":"19","author":"Ferrari","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105954_bib0385","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jbmr\/zjae023","article-title":"Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition","volume":"39","author":"Kim","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105954_bib0390","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105954_bib0395","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jbmr\/zjae170","article-title":"The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation","volume":"40","author":"Schini","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105954_bib0400","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41413-024-00362-4","article-title":"Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect","volume":"12","author":"El-Masri","year":"2024","journal-title":"Bone Res"},{"issue":"18","key":"10.1016\/j.jbspin.2025.105954_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.167790","article-title":"Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation","volume":"8","author":"Fu","year":"2023","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105954_bib0410","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105954_bib0415","first-page":"114","article-title":"Mechanical basis of bone strength: influence of bone material, bone structure and muscle action","volume":"17","author":"Hart","year":"2017","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105954_bib0420","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2025.105954_bib0425","doi-asserted-by":"crossref","first-page":"115830","DOI":"10.1016\/j.bone.2020.115830","article-title":"Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study","volume":"144","author":"Everts-Graber","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.jbspin.2025.105954_bib0430","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.bonr.2020.100290","article-title":"Effect of risedronate on bone loss at discontinuation of denosumab","volume":"13","author":"Laroche","year":"2020","journal-title":"Bone Rep"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105954_bib0435","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","article-title":"Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis","volume":"103","author":"Popp","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105954_bib0440","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105954_bib0445","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"Solling","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2025.105954_bib0450","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105954_bib0455","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporos Int"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105954_bib0460","doi-asserted-by":"crossref","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105954_bib0465","doi-asserted-by":"crossref","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105954_bib0470","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-024-07351-7","article-title":"Clinical experience with denosumab discontinuation","volume":"36","author":"Laursen","year":"2025","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2025.105954_bib0475","doi-asserted-by":"crossref","first-page":"116498","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.jbspin.2025.105954_bib0480","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.bonr.2020.100290","article-title":"Effect of risedronate on bone loss at discontinuation of denosumab","volume":"13","author":"Laroche","year":"2020","journal-title":"Bone Rep"},{"issue":"12","key":"10.1016\/j.jbspin.2025.105954_bib0485","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105954_bib0490","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.jbspin.2025.105954_bib0495","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00198-024-07213-2","article-title":"One versus 2 years of alendronate following denosumab: the CARD extension","volume":"35","author":"Tsai","year":"2024","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2025.105954_bib0500","first-page":"1","article-title":"Effects of sequential anti-resorptive agents on bone mineral density following denosumab withdrawal: a multicenter real-world study in Korea (MAXCARE study)","author":"Ha","year":"2025","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105954_bib0505","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105954_bib0510","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/EJE-21-0157","article-title":"Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence","volume":"185","author":"Grassi","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105954_bib0515","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/jbmr\/zjaf008","article-title":"Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition","volume":"40","author":"Kim","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105954_bib0520","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","article-title":"The comparison of alendronate and raloxifene after denosumab (CARD) study: a comparative efficacy trial","volume":"35","author":"Ramchand","year":"2024","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105954_bib0525","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105954_bib0530","doi-asserted-by":"crossref","first-page":"pe255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9999","key":"10.1016\/j.jbspin.2025.105954_bib0535","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105954_bib0540","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","article-title":"Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis","volume":"31","author":"Ebina","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105954_bib0545","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","article-title":"Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women","volume":"33","author":"Ha","year":"2022","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105954_bib0550","doi-asserted-by":"crossref","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"88","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105954_bib0555","doi-asserted-by":"crossref","first-page":"100288","DOI":"10.1016\/j.bonr.2020.100288","article-title":"Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report","volume":"13","author":"Kashii","year":"2020","journal-title":"Bone Rep"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105954_bib0560","doi-asserted-by":"crossref","first-page":"105754","DOI":"10.1016\/j.jbspin.2024.105754","article-title":"Progression of multiple vertebral fractures after denosumab discontinuation under treatment with romosozumab. A case-report","volume":"91","author":"Krikelis","year":"2024","journal-title":"Joint Bone Spine"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105954_bib0565","doi-asserted-by":"crossref","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"6","key":"10.1016\/j.jbspin.2025.105954_bib0570","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00198-021-06261-2","article-title":"Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment","volume":"33","author":"Tominaga","year":"2022","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105954_bib0575","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40618-025-02542-3","article-title":"Early administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study","volume":"48","author":"Piasentier","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105954_bib0580","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00198-024-07139-9","article-title":"A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis","volume":"35","author":"Kumar","year":"2024","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105954_bib0585","doi-asserted-by":"crossref","first-page":"e10731","DOI":"10.1002\/jbm4.10731","article-title":"Discontinuation of denosumab: gradual decrease in doses preserves half of the bone mineral density gain at the lumbar spine","volume":"7","author":"Laroche","year":"2023","journal-title":"JBMR Plus"},{"key":"10.1016\/j.jbspin.2025.105954_bib0590","doi-asserted-by":"crossref","first-page":"886579","DOI":"10.3389\/fbioe.2022.886579","article-title":"Assessment of strategies for safe drug discontinuation and transition of denosumab treatment in PMO-insights from a mechanistic PK\/PD model of bone turnover","volume":"10","author":"Martinez-Reina","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.jbspin.2025.105954_bib0595","doi-asserted-by":"crossref","first-page":"116764","DOI":"10.1016\/j.bone.2023.116764","article-title":"Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study","volume":"172","author":"Liebich","year":"2023","journal-title":"Bone"},{"issue":"9886","key":"10.1016\/j.jbspin.2025.105954_bib0600","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25001162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25001162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T20:01:52Z","timestamp":1772568112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X25001162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1297319X25001162"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105954","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for denosumab discontinuation in postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105954"}}